Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...

CLL develops in a type of white blood cell called lymphocytes. The rapid division of lymphocytes can crowd out healthy blood cells. Over time, this can lead to symptoms like: anemia abnormal ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

The start of NX-5948's CLL registrational trial in 2025 As of ... starting with warm Autoimmune Hemolytic Anemia (wAIHA), represents a significant growth opportunity. The autoimmune disease ...

About 200 kids are diagnosed with cancer in South Carolina each year, and most are followed for years afterward by doctors.

An Aussie family has made a heartbreaking discovery after their five-year-old daughter struggled to open Christmas presents ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

Gladstone Institutional Advisory LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 18.9% in the fourth ...

Amgen (NASDAQ:AMGN – Get Free Report) had its target price increased by Piper Sandler from $310.00 to $329.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently ...